Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|August 17, 2016

South Tees Bio-Incubator Launches in the UK

The bio-incubator, located at the James Cook University Hospital, will give early-stage biotechnology and life-sciences companies access to facilities to support biomedical research.

The South Tees Bio-Incubator launched on August 9, 2016 at the James Cook University Hospital in Middlesbrough, United Kingdom, the Centre for Process Innovation (CPI) said in a press announcement. The Bio-Incubator space will give early-stage biotechnology and life-sciences companies access to facilities to support innovations in biomedical research.

CPI and the Northern Health Science Alliance (NHSA) are strategic partners in the initiative, which is being led by the South Tees Hospitals NHS Foundation Trust. The Bio-incubator provides access to specialist facilities, expert advice, and shared laboratory space that can be used by companies within the bio-medical sector to develop technologies and ideas that could potentially benefit the healthcare industry. The first tenants to use the Bio-Incubator space are GlycoSeLect Ltd, a spin out of Dublin City University, who specialize in the development of glycoprotein separation technology for analysis and manufacturing used in biopharmaceutical production.

“Our aim is to create a leading-edge hub at the heart of our clinical research campus to accelerate collaboration, technology and knowledge exchange, and open innovation,” Andrew Owens, the Trust’s director of Innovation and consultant Cardiac Surgeon, said in a press announcement. “It’s now widely acknowledged that research, innovation, and entrepreneurship are crucial driving factors for the North East’s long-term efficiency, competitiveness, and economic growth, and initiatives such as this mean the Trust can develop deep and high value partnerships.”

Source: CPI

 


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.